RenBio Completes $24 Million Series A Financing and Licenses Novel SARS-CoV-2 Bispecific Antibody from Columbia University

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3u8tMEG
via IFTTT